GLP-1 TV · Patient story · views checked Oct 2026
GLP1 GLOVES ARE OFF: Wegovy Deal From Novo Nordisk vs Semaglutide Compound Hims And Hers
Patient story
Our summary
According to the video, Novo Nordisk is ending its working relationship with Hims and Hers because the telehealth company continues to sell compounded semaglutide. The host says this surprised her, since the two companies had announced a plan in April to sell Wegovy directly to patients, alongside Ro and LifeMD. She cites Axios for the report that Novo Nordisk said it is deeply concerned about knockoff drugs made with foreign ingredients, and that Hims and Hers stock fell sharply while Novo Nordisk shares dropped 6% in pre-market trading on Monday, June 23.
One person's experience, in their words. Not medical advice.
Where Wegovy costs least today
The three cheapest partner programs for Wegovy, all in per month, checked weekly. Brand Wegovy and compounded versions are different products; each row says which it is.
What else the video covers
She then lays out the background. She says Ro stopped offering compounded semaglutide on May 21, 2025 but still sells Wegovy through a partnership with Novo Nordisk. She also says a federal court ruled that the FDA acted lawfully when it removed Ozempic and Wegovy from the drug shortage list, rejecting a challenge from a compounding pharmacy group. Her own guess, which she labels opinion, is that Hims and Hers kept selling compounds because of the money involved. She also compares Novo Nordisk, which is Europe-based, with Eli Lilly, which she describes as more aggressive in lawsuits.
The second half covers other topics. She says the semaglutide patent is expected to end in Canada in January 2026, and that Canadians could then get a generic for around $70 per month, compared with about $500 per month now. She discusses whether Americans could legally cross the border for personal-use supplies, and says more information is needed. She also mentions upcoming videos on pipeline drugs, Amazon Prime Day coverage, an HSN appearance, and her own fitness plans.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:00 She reports that Novo Nordisk is ending its working relationship with Hims and Hers because the company still sells compounded semaglutide.
- 1:33 She cites Axios for Novo Nordisk's stated concern about knockoff drugs made with foreign ingredients, and for the stock drops on June 23.
- 3:38 She says Ro stopped offering compounded semaglutide on May 21, 2025 and still sells Wegovy through a Novo Nordisk partnership.
- 5:10 She says a federal court upheld the FDA's removal of Ozempic and Wegovy from the shortage list, rejecting the compounders' challenge.
- 7:47 She offers her own opinion that Hims and Hers kept selling compounds for financial reasons, and compares Novo Nordisk with Eli Lilly.
- 11:51 She says Canada's semaglutide patent ends in January 2026, with a generic expected near $70 per month versus about $500 now.
Key moments
From the creator's own chapters. Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Wegovy and semaglutide
- Prices mentioned
- $70 a month and $500 a month
- Who is speaking
- Patient
Questions this video answers
Why did Novo Nordisk end its relationship with Hims and Hers?
According to the video, Novo Nordisk objected to Hims and Hers continuing to sell compounded semaglutide. The host cites Axios reporting that Novo Nordisk called these products knockoffs made with foreign ingredients that are not FDA approved.
Does Ro still sell Wegovy after stopping compounded semaglutide?
The host says Ro stopped offering compounded semaglutide on May 21, 2025. She says Ro still sells brand-name Wegovy through a direct partnership with Novo Nordisk.
How much could generic semaglutide cost in Canada in 2026?
She says the patent is expected to end in Canada in January 2026. She says Canadians could then pay around $70 per month for a generic, compared with about $500 per month now, and adds that rules on crossing the border for medication would need checking.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Novo Nordisk CEO on Hims Suit, Wegovy Demand and PricingIn this Bloomberg Television interview, the Novo Nordisk chief executive responds to questions about Hims & Hers, the company's 2026 outlook, its oral Wegovy pill and its search for acquisitions.
HIMS: Compound Semaglutide OUT, Branded InThe host of On The Pen opens this March 9 live stream with news that Novo Nordisk and Hims & Hers have reached a deal.
Novo Nordisk’s Canadian drug patent lapses, opening market for Hims & Her HealthAccording to this CNBC segment, Novo Nordisk will lose its exclusive Canadian patent on semaglutide, the ingredient in its top-selling drugs Ozempic and Wegovy, next January.
Semaglutide Wars: Novo Sues Hims over Patent InfringementThe host of On The Pen says a lot happened in the three days before this February 9, 2026 live stream.
Novo Sues Amble, Drops Wegovy Starting PriceIn this short live stream from the On The Pen GLP-1 News channel, the host goes over two stories from that day.
About Countess of Shopping
Patient story, 135K subscribers. 10 of their videos are in GLP-1 TV, 233K views between them, mostly on Mounjaro, Zepbound, Compounded semaglutide.
- MOUNARO 2.5 mg FOR WEIGHT LOSS - EVERYTHING YOU NEED TO KNOW! (Mounjaro Tirzepatide Weight Loss)
- 12 LB WEIGHT LOSS MOUNJARO WEIGHT LOSS WEEK 1💥 Mounjaro Tirzepatide Weight Loss Journey
- BREAKING: Zepbound Prices PLUMMET 📉 (What This Means For You)
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Generic Ozempic: none in the US until December 2031, where generics already sell, and what to buy instead
No. There is no FDA-approved generic Ozempic or Wegovy in the US, and the FDA Orange Book lists Novo Nordisk's semaglutide compound patent until 5 December 2031. Generics went on sale in India in March 2026 and in Canada in May, but a US buyer cannot legally import them. What you can buy today: compounded semaglutide from $69 a month on our board, or Novo's own self-pay Wegovy at $349 a month for the pen and from $149 for the pill.
- Compounded semaglutide vs Wegovy: same molecule, different rules, and what the price gap buys
Same molecule, not the same product: Wegovy is FDA-approved and $349/mo from Novo; compounded semaglutide is unreviewed and far cheaper. The gap, live.
- CagriSema: FDA decision due by the end of 2026, no price yet, and how it compares with Zepbound and Wegovy
CagriSema is not FDA-approved and has no price yet. Novo Nordisk filed it with the FDA on December 18, 2025 and expects a decision in the fourth quarter of 2026, with a full US launch at the start of 2027. In REDEFINE 1 it cut weight by 20.4% at 68 weeks, but head to head it trailed tirzepatide, 20.2% against 23.6%. Until it launches, compounded semaglutide starts at $69 a month on our board.
Find more like it
Side effectsCost and insuranceExercise and strengthStopping and maintenance
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.